NCT07069465View on ClinicalTrials.gov

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

flotufolastat F 18

PSMA-PET scan with Posluma agent (x2)

DRUG

Relugolix 120 MG

Administration of oral ADT for 3 and 6 weeks

DIAGNOSTIC_TEST

Serum PSA and Testosterone

Serum PSA and testosterone at study initiation and again at 3 and 6 weeks after initiation of ADT

Trial Locations (1)

75231

Urology Clinics of North Texas, Dallas

Sponsors

Collaborators (1)

Blue Earth Diagnostics
All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

collaborator

Texas Health Resources

OTHER

lead

Urology Clinics of North Texas

NETWORK